Evidence mapPaperPMID 42423773Full record

ReviewMolecular biomedicine2026

Interleukin-8 in health and disease.

Chiara Bazzichetto, Emanuela Dell'Aquila, Margherita Veroli, Lorenzo Belluomini, Adele Bonato, Giovanni Bernardini, Michele Bevilacqua, Filippo Cattazzo, Andrea Dalbeni, Tarcisio Michele Tampu and 5 more

Abstract readReview
In one paragraph

Review in Molecular biomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Chiara BazzichettoPreclinical Models and New Therapeutic Agents Unit, IRCCS - Regina Elena National Cancer Institute, Rome, Italy. chiara.bazzichetto@ifo.it.ORCID http://orcid.org/0000-0002-1648-3700
Emanuela Dell'AquilaDivision of Medical Oncology 2, IRCCS - Regina Elena National Cancer Institute, Rome, Italy.ORCID http://orcid.org/0000-0002-7258-1364
Margherita VeroliDivision of Medical Oncology 2, IRCCS - Regina Elena National Cancer Institute, Rome, Italy.
Lorenzo BelluominiSection of Innovation Biomedicine - Oncology Area, Department of Engineering for Innovation Medicine (DIMI), University of Verona, and Verona University and Hospital Trust (AOUI), Verona, Italy.ORCID http://orcid.org/0000-0003-1981-5499
Adele BonatoSection of Innovation Biomedicine - Oncology Area, Department of Engineering for Innovation Medicine (DIMI), University of Verona, and Verona University and Hospital Trust (AOUI), Verona, Italy.
Giovanni BernardiniDepartment of Molecular Medicine, Sapienza University of Rome, Rome, Italy.ORCID http://orcid.org/0000-0002-3705-2598
Michele BevilacquaSection of General Medicine C and Liver Unit, University and Azienda Ospedaliera, Universitaria Integrata of Verona, Verona, Italy.ORCID http://orcid.org/0000-0001-5647-2822
Filippo CattazzoSection of General Medicine C and Liver Unit, University and Azienda Ospedaliera, Universitaria Integrata of Verona, Verona, Italy.ORCID http://orcid.org/0000-0003-1316-3311
Andrea DalbeniSection of General Medicine C and Liver Unit, University and Azienda Ospedaliera, Universitaria Integrata of Verona, Verona, Italy.ORCID http://orcid.org/0000-0003-0402-4176
Tarcisio Michele TampuSection of Innovation Biomedicine - Department of Engineering for Innovation Medicine (DIMI), University of Verona, Verona, Italy.ORCID http://orcid.org/0009-0009-0051-4910
Valentina SalariSection of Innovation Biomedicine - Department of Engineering for Innovation Medicine (DIMI), University of Verona, Verona, Italy.ORCID http://orcid.org/0000-0002-8769-6498
Paolo Francesco FabeneSection of Innovation Biomedicine - Department of Engineering for Innovation Medicine (DIMI), University of Verona, Verona, Italy.ORCID http://orcid.org/0000-0002-9644-4399
Claudio LuchiniSection of Pathology, Department of Diagnostics and Public Health - ARC-Net Research Center, University of Verona, Verona, Italy.ORCID http://orcid.org/0000-0003-4901-4908
Michele MilellaSection of Innovation Biomedicine - Oncology Area, Department of Engineering for Innovation Medicine (DIMI), University of Verona, and Verona University and Hospital Trust (AOUI), Verona, Italy.ORCID http://orcid.org/0000-0002-3826-5237
Fabiana ConciatoriPreclinical Models and New Therapeutic Agents Unit, IRCCS - Regina Elena National Cancer Institute, Rome, Italy. fabiana.conciatori@ifo.it.ORCID http://orcid.org/0000-0002-8579-5222

Funding

H2020 Marie Skłodowska-Curie Actions 101179447
6 · The paper itself

Abstract

Cytokines are among the main factors involved in indirect cell-to-cell communication in physiological and pathological conditions. In this way, cytokines are soluble and tissue-resident easily detectable biomarkers for the diagnosis and the prediction of clinical outcome, as well as drug targets. Over the years, the pleiotropic IL-8 gained a central role in the pathogenesis of several immunological disorders, spanning from autoimmune pathologies and sepsis to neurological, liver and cardiovascular diseases. In several solid cancers, IL-8 not only serves as a prognostic biomarker but also as predictive tool. Increasing evidence highlighted IL-8 as a prognostic/predictive biomarker even for immunotherapy to stratify eligible patients, to avoid unnecessary toxicity and progression. Today, a comprehensive review covering IL-8 in all these fields has not yet been published. Hence, we aim to provide preclinical and clinical evidence on the biology and functions of IL-8, involved in the pathogenesis of non-malignant diseases, including inflammatory bowel diseases, sepsis, neuroinflammation, liver and cardiovascular pathologies. In oncology area, we will describe the pro-tumorigenic roles, including the characterization of the immunosuppressive microenvironment, also discussing the implications of direct/indirect IL-8 targeting and the involvement of gut microbiota. Unfortunately, the main obstacles to establish IL-8 as a useful non-invasive clinical tool for diagnosis and treatments' selection are the lack of the standardization of method detection and the source of IL-8 production.

Indexed as

Interleukin-8AnimalsBiomarkersHumansNeoplasmsBiomarkersInterleukin-8BiomarkerCancerImmune systemInterleukin-8Non-malignant diseases

Identifiers

PMID42423773
PMCPMC13350614

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.